Chemotherapy and biologic use in the routine management of metastatic colorectal cancer in Australia: is clinical practice following the evidence?

C Semira; HL Wong; K Field; M Lee; B Lee; L Nott; J Shapiro; R Wong; J Tie; B Tran; G Richardson; A Zimet; L Lipton; B Tamjid; M Burge; B Ma; J Johns; M Harold; P Gibbs

Journal article

Chemotherapy and biologic use in the routine management of metastatic colorectal cancer in Australia: is clinical practice following the evidence?

C Semira, HL Wong, K Field, M Lee, B Lee, L Nott, J Shapiro, R Wong, J Tie, B Tran, G Richardson, A Zimet, L Lipton, B Tamjid, M Burge, B Ma, J Johns, M Harold, P Gibbs

Internal Medicine Journal | WILEY | Published : 2019

DOI: 10.1111/imj.14115

Download PDF

Abstract

Background: Emerging evidence on the optimal use of chemotherapy and biologics in patients with metastatic colorectal cancer should impact management in routine care. Recent studies have demonstrated benefits for initial triplet chemotherapy (5-fluorouracil, oxaliplatin and irinotecan, FOLFOXIRI) and for initial treatment with an epidermal growth factor receptor inhibitor (EGFRi) in patients with a RAS wild-type tumour and a left-sided primary tumour. Aim: To explore evolving pattern of metastatic colorectal cancer care over time in Australia. Methods: We analysed data from the Treatment of Recurrent and Advanced Colorectal Cancer registry. Results: From July 2009 to December 2017, 2552 meta..

View full abstract